Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses

Journal of the National Cancer Institute

Volumn 106, Issue 6, 2014, Pages

  Lee, Jung Min ^a   Hays, John L ^a   Annunziata, Christina M ^a   Noonan, Anne M ^a   Minasian, Lori ^a   Zujewski, Jo Anne ^a   Yu, Minshu ^a   Gordon, Nicolas ^a   Ji, Jiuping ^b   Sissung, Tristan M ^a   Figg, William D ^a   Azad, Nilofer ^a   Wood, Bradford J ^a   Doroshow, James ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; ESTROGEN RECEPTOR; OLAPARIB; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSCRIPTION FACTOR FKHRL1; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ADULT; AGED; ANEMIA; ANOREXIA; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DEHYDRATION; DNA REPAIR; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HUMAN; HUMAN CELL; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEOMICS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; DRUG ADMINISTRATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; MONOCYTE; MUTATION; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PREDICTIVE VALUE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MONOCYTES; MUTATION; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY ADENOSINE DIPHOSPHATE RIBOSE; PREDICTIVE VALUE OF TESTS;

EID: 84905187284     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju089     Document Type: Article

References (59)

1. Hoeijmakers JH. DNA repair mechanisms. Maturitas. 2001;38(1):17-22; discussion 22-23.
2. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs. 2009;18(1):31-43.
3. Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) poly-merase as a novel therapeutic target in cancer. Clin Cancer Res. 2010;16(18):4517-4526.
4. Tomoda T, Kurashige T, Moriki T, et al. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol. 1991;37(4):223-227.
5. Barnett JC, Bean SM, Nakayama JM, et al. High poly(adenosine diphos-phate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer. Obstet Gynecol. 2010;115(1):49-54.
6. Bieche I, de Murcia G, Lidereau R. Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer. Clin Cancer Res. 1996;2(7):1163-1167.
7. Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193-204.
8. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA. 2011;108(8):3406-3411.
9. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-921.
10. Hartwell LH, Szankasi P, Roberts CJ, et al. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278(5340):1064- 1068.
11. Iglehart JD, Silver D P. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med. 2009;361(2):189-191.
12. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-917.
13. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372-379.
14. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
15. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-2519.
16. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245- 251.
17. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
18. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
19. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-2663.
20. Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22(6):1346- 1352.
21. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26(1):20-25.
22. Nguewa PA, Fuertes MA, Cepeda V, et al. Poly(ADP-ribose) poly-merase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem. 2006;2(1):47-53.
23. Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 2011;17(4):783-791.
24. BayesMendel Lab. http://bcb.dfci.harvard.edu/bayesmendel/brcapro.php. Accessed October 12, 2013.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
26. Kinders RJ, Hollingshead M, Khin S, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res. 2008;14(21):6877-6885.
27. Gao R, Price DK, Sissung T, et al. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther. 2008;7(5):1246-1250.
28. Lee JM, Hays JL, Noonan AM, et al. Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. Cancer. 2013;119(7):1357-1364.
29. Azad N, Yu M, Davidson B, et al. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Mol Cell Proteomics. 2013;12(6):1621-1631.
30. Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007;110(2):309-317.
31. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacody-namic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007;109(7):1323-1330.
32. Winters M, Dabir B, Yu M, et al. Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics. 2007;7(22):4066-4068.
33. Rasool N, LaRochelle W, Zhong H, et al. Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res. 2010;16(2):600-609.
34. MD Anderson Cancer Center. http://www.mdanderson.org/education-and- research/resources-for-professionals/scientific-resources/core-facil-ities-and- services/functional-proteomics-rppa-core/index.html. Accessed March 26, 2014.
35. Jackson S, Ghali L, Harwood C, et al. Reduced apoptotic levels in squa-mous but not basal cell carcinomas correlates with detection of cutaneous human papillomavirus. Br J Cancer. 2002;87(3):319-323.
36. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800-802.
37. Yang JY, Yoshihara K, Tanaka K, et al. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest. 2013;123(12):5410.
38. Cardnell RJ, Feng Y, Diao L, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013;19(22):6322-6328.
39. Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013;109(4):1072-1078.
40. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14(9):882-892.
41. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382- 1392.
42. Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012;18(6):1726-1734.
43. Oza AM, Cibula D, Oaknin A, Poole CJ, Mathijssen RHJ, Sonke GS, Colombo N, Špacek J, Vuylsteke P, Hirte HW, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Tchakov I, Friedlander M. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol. 2012;30(Suppl):abstract 5001.
44. Rajan A, Carter CA, Kelly RJ, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18(8):2344-2351.
45. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin GJ, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Macpherson E, Dougherty B, Jürgensmeier JM, Orr M, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol. 2013;31(Suppl):abstract 5505.
46. Safra T, Borgato L, Nicoletto MO, et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011;10(10):2000-2007.
47. Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366-375.
48. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous recombination predicts pathologic complete response to neoad-juvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010;16(24):6159-6168.
49. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
50. Veeck J, Ropero S, Setien F, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol. 2010;28(29):e563-e564; author reply e565-e566.
51. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(44):18032-18037.
52. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705-2711.
53. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle. 2010;9(6):1091-1096.
54. Tsai WB, Chung YM, Takahashi Y, et al. Functional interaction between FOXO3a and ATM regulates DNA damage response. Nat Cell Biol. 2008;10(4):460-467.
55. Chung YM, Park SH, Tsai WB, et al. FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat Commun. 2012;3:1000. doi:1000.10.1038/ncomms2008
56. Pettersson F, Yau C, Dobocan MC, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res. 2011;17(9):2874-2884.
57. Coleman LJ, Peter MB, Teall TJ, et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer. 2009;100(9):1393-1399.
58. Ross JS, Ali SM, Wang K, et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol. 2013;130(3):554-559.
59. Sillanpaa S, Anttila M, Voutilainen K, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol. 2007;104(2):296-303.